The Development of a Nano-based Approach to Alleviate Cisplatin-Induced Ototoxicity
Cisplatin-induced hearing loss is experienced by a high percentage of patients with squamous cell carcinoma undergoing cisplatin chemotherapy. A novel nano-construct capable of sequestering extracellular cisplatin was developed to combat this problem. The nano-construct consisted of superparamagnetic iron oxide nanoparticles (SPIONs) entrapped within polymeric micelles, which were formed from a glutathione diethyl ester-conjugated amphiphilic diblock copolymer. The glutathione-micelles were analyzed at the cellular level and in an organotypic study for safety evaluation. All utilized methods indicated that the micelles do not cause cellular toxicity or organ damage. The micelles’ ability to reduce cisplatin-induced cytotoxicity was then probed in an in vitro model. Cisplatin was pre-treated with the novel nano-construct before being added to growing cells. When compared to cells that were exposed to untreated cisplatin, cells in the pre-treated cisplatin group showed a significant increase in cell viability. This clearly demonstrates that the construct is able to protect the cells from cisplatin cytotoxicity and makes it highly likely that the novel nano-construct will be able to play a role in the protection of the inner ear from cisplatin-induced ototoxicity.
Keywordscisplatin thiol nanomicelles cisplatin-induced ototoxicity inner ear
This work was funded through a National Institute of Health (NIH) grant: 1R01DC014464-01. The authors would like to thank Zheng Cui and Lucia Morstadt for their technical assistance. The authors would also like to thank Dr. Kalinec at UCLA for the donation of the HEI-OC1 cell line.
Compliance with Ethical Standards
Animal care and use was in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of The University of Pennsylvania and of the National Institute of Health.
Conflict of Interest
The authors declare that they have no conflicts of interest.
- Callejo A, Sedó-Cabezón L, Juan ID, Llorens J (2015) Cisplatin-induced ototoxicity: effects, mechanisms and protection strategies. Toxics 3:268-293Google Scholar
- Freyer DR, Chen L, Krailo MD, Knight K, Villaluna D, Bliss B, Pollock BH, Ramdas J, Lange B, van Hoff D, VanSoelen ML, Wiernikowski J, Neuwelt EA, Sung L (2017) Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18(1):63–74. https://doi.org/10.1016/S1470-2045(16)30625-8 CrossRefPubMedGoogle Scholar
- Katzenstein HM, Chang KW, Krailo M, Chen Z, Finegold MJ, Rowland J, Reynolds M, Pappo A, London WB, Malogolowkin M, for the Children's Oncology Group (2009) Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer 115(24):5828–5835. https://doi.org/10.1002/cncr.24667 CrossRefPubMedPubMedCentralGoogle Scholar
- Lee JW, Pussegoda K, Rassekh SR, Monzon JG, Liu G, Hwang S, Bhavsar AP, Pritchard S, Ross CJ, Amstutz U, Carleton BC, CPNDS Clinical Recommendations Group (2016) Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using pharmacogenetic markers. Ther Drug Monit 38(4):423–431. https://doi.org/10.1097/FTD.0000000000000298 CrossRefPubMedGoogle Scholar
- Mahajan S, Koul V, Choudhary V, Shishodia G, Bharti AC (2013) Preparation and in vitro evaluation of folate-receptor-targeted SPION-polymer micelle hybrids for MRI contrast enhancement in cancer imaging. Nanotechnology 24(1):015603. https://doi.org/10.1088/0957-4484/24/1/015603 CrossRefPubMedGoogle Scholar
- McQuade C, al Zaki A, Desai Y, Vido M, Sakhuja T, Cheng Z, Hickey RJ, Joh D, Park SJ, Kao G, Dorsey JF, Tsourkas A (2015) A multifunctional nanoplatform for imaging, radiotherapy, and the prediction of therapeutic response. Small 11(7):834–843. https://doi.org/10.1002/smll.201401927 CrossRefPubMedGoogle Scholar
- Thompson DC, Wyrick SD, Holbrook DJ, Chaney SG (1995) HPLC and 31P NMR characterization of the reaction between antitumor platinum agents and the phosphorothioate chemoprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). Biochem Pharmacol 50(9):1413–1419. https://doi.org/10.1016/0006-2952(96)84545-X CrossRefPubMedGoogle Scholar
- Yoo J, Hamilton SJ, Angel D, Fung K, Franklin J, Parnes LS, Lewis D, Venkatesan V, Winquist E (2014) Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients. Laryngoscope 124(3):E87–E94. https://doi.org/10.1002/lary.24360 CrossRefPubMedGoogle Scholar